Breakthrough research identifies TIM3 as a key target in MAPK-activated pediatric gliomas, offering new hope for more effective immunotherapy treatments. Despite being a leading cause of childhood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback